EUCTR2021-005085-18-Outside-EU/EEA
Active, not recruiting
Phase 1
Open-label Study to Evaluate the Pharmacokinetics, Safety, and Immunogenicity of Ustekinumab in Pediatric Participants - U-POPS (Ustekinumab Pediatric Opportunistic PK Study)
ConditionsPediatric psoriasis(PsO)Juvenile psoriatic arthritis (jPsA)MedDRA version: 20.0Level: PTClassification code 10076674Term: Juvenile psoriatic arthritisSystem Organ Class: 10028395 - Musculoskeletal and connective tissue disordersMedDRA version: 20.0Level: PTClassification code 10037153Term: PsoriasisSystem Organ Class: 10040785 - Skin and subcutaneous tissue disordersTherapeutic area: Body processes [G] - Immune system processes [G12]
DrugsSTELARA®
Overview
- Phase
- Phase 1
- Intervention
- Not specified
- Conditions
- Pediatric psoriasis(PsO)Juvenile psoriatic arthritis (jPsA)
- Sponsor
- Janssen Research & Development, LLC
- Status
- Active, not recruiting
- Last Updated
- last year
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- •Age and Disease Characteristics
- •1\. \=5 to \<18 years of age, inclusive, with a diagnosis of jPsA (ie, ILAR or Vancouver criteria) by qualified HCP.
- •\=6 to \<18 years of age, inclusive, with a diagnosis of pediatric PsO by a qualified HCP.
- •Type of Participant
- •2\. Initiated ustekinumab treatment \=16 weeks prior to enrollment and received 3 or more doses of ustekinumab prior to enrollment.
- •Informed Consent
- •3\. Parent(s) (preferably both if available or as per local requirements) (or their legally acceptable representative) must sign an informed consent form (ICF) indicating that he or she understands the purpose of, and procedures required for, the study and is willing to allow the child to participate in the study. Assent is also required of children capable of understanding the nature of the study.
- •Are the trial subjects under 18? yes
- •Number of subjects for this age range: 75
- •F.1\.2 Adults (18\-64 years) no
Exclusion Criteria
- •Any potential participant who meets any of the following criteria will be excluded from
- •participating in the study.
- •1\. Has poor tolerability of venipuncture or lack of adequate venous access for required blood sampling.
- •2\. Has any condition that, in the opinion of the investigator, participation would not be in the best interest of the participant (eg, compromise the well\-being) or that could prevent, limit, or confound the protocol\-specified assessments.
- •3\. If currently enrolled in an investigational study, contact the Study Responsible Physician to discuss eligibility for inclusion in study.
Outcomes
Primary Outcomes
Not specified
Similar Trials
Completed
Phase 1
Open-label study to assess how the pharmacokinetics (i.e. the way the body absorbs, distributes and gets rid of a drug), safety, and tolerability of the drug siponimod are influenced by the presence of specific genetic characteristics (namely CYP2C9 genotypes).The medical condition pursued for siponimod is Secondary Progressive Multiple Sclerosis (SPMS). This study aims to characterize the PK profile of siponimod in healthy subjects with the CYP2C9 extensive and poor metabolizer phenotype.Neurological - Multiple sclerosisACTRN12613000545763ovartis Pharmaceuticals Australia Pty Limited24
Completed
Not Applicable
An open-label study to assess the pharmacokinetics and safety/tolerability of pulsatile intra-vaginal delivery of a single dose of oxybutynin in healthy femalesNL-OMON51105iGalli BV8
Completed
Phase 1
A study in healthy male volunteers to investigate how the test medicine is taken up, processed, and removed from the bodyPharmacokinetics, mass balance and metabolite profiles of NRD135S.E1 in healthy adult male volunteersNot ApplicableISRCTN51059297ovaremed AG (Switzerland)8
Active, not recruiting
Phase 1
A study in which the blood levels of the antibiotic fidaxomicin are studied in patients with an inflammation of the intestine and concomitantly an infection of the gut caused by bacteria called Clostridium difficile.EUCTR2014-003002-32-PLAstellas Pharma Europe Ltd.40
Active, not recruiting
Phase 1
A study in which the blood levels of the antibiotic fidaxomicin are studied in patients with an inflammation of the intestine and concomitantly an infection of the gut caused by bacteria called Clostridium difficile.Clostridium Difficile Infection (CDI) also known as C. difficile-associated diarrhoea (CDAD)MedDRA version: 19.0Level: LLTClassification code 10022661Term: Intestinal infection due to clostridium difficileSystem Organ Class: 100000004862Therapeutic area: Diseases [C] - Bacterial Infections and Mycoses [C01]EUCTR2014-003002-32-ATAstellas Pharma Europe Ltd.25